These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 27084133)

  • 1. ["Victoria surprised us"].
    Wahle K; Schumacher B
    MMW Fortschr Med; 2016 Mar; 158(6):16. PubMed ID: 27084133
    [No Abstract]   [Full Text] [Related]  

  • 2. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.
    Skowronski DM; Janjua NZ; Sabaiduc S; De Serres G; Winter AL; Gubbay JB; Dickinson JA; Fonseca K; Charest H; Bastien N; Li Y; Kwindt TL; Mahmud SM; Van Caeseele P; Krajden M; Petric M
    J Infect Dis; 2014 Jul; 210(1):126-37. PubMed ID: 24446529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canadian influenza serosurvey prior to the 1992-1993 season.
    Can Commun Dis Rep; 1992 Nov; 18(22):161-6. PubMed ID: 1291010
    [No Abstract]   [Full Text] [Related]  

  • 4. [Influenza live attenuated intra-nasal vaccines].
    Weil-Olivier C
    Arch Pediatr; 2010 Jun; 17(6):904-5. PubMed ID: 20654953
    [No Abstract]   [Full Text] [Related]  

  • 5. [Quadrivalent influenza vaccines].
    Wutzler P; Dietz B; Hardt R; Hoins L; Knuf M; Wahle K
    MMW Fortschr Med; 2015 Sep; 157(15):60-2. PubMed ID: 26349732
    [No Abstract]   [Full Text] [Related]  

  • 6. Influenza B Burden in Latin America and Potential Benefits of the New Quadrivalent Vaccines.
    Falleiros Arlant LH; Bricks LF
    J Pediatric Infect Dis Soc; 2016 Mar; 5(1):1-2. PubMed ID: 26803330
    [No Abstract]   [Full Text] [Related]  

  • 7. New options for influenza vaccines: quadrivalent, recombinant, and cell culture.
    Brokhof MM; Foster SL; Hayney MS
    J Am Pharm Assoc (2003); 2013; 53(5):545-9. PubMed ID: 24030133
    [No Abstract]   [Full Text] [Related]  

  • 8. Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay J; Fonseca K; Charest H; Krajden M; Petric M; Mahmud SM; Van Caeseele P; Bastien N; Eshaghi A; Li Y
    J Infect Dis; 2015 Sep; 212(5):726-39. PubMed ID: 25784728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolutionary pattern of reemerging influenza B/Victoria lineage viruses in São Paulo, Brazil, 1996-2012: Implications for vaccine composition strategy.
    Paiva TM; Benega MA; Silva DB; Santos KC; Cruz AS; Hortenci MF; Barbieri MT; Monteiro MM; Barbosa HA; Carvalhanas TR
    J Med Virol; 2013 Nov; 85(11):1983-9. PubMed ID: 23926069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 1993-94 season.
    Can Commun Dis Rep; 1993 May; 19(9):65-71. PubMed ID: 7686070
    [No Abstract]   [Full Text] [Related]  

  • 11. Influenza vaccine 2008-2009.
    Med Lett Drugs Ther; 2008 Oct; 50(1296):77-9. PubMed ID: 18833032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012.
    Heikkinen T; Ikonen N; Ziegler T
    Clin Infect Dis; 2014 Dec; 59(11):1519-24. PubMed ID: 25139969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using surveillance to evaluate influenza vaccine effectiveness.
    Jackson LA
    J Infect Dis; 2009 Jan; 199(2):155-8. PubMed ID: 19086916
    [No Abstract]   [Full Text] [Related]  

  • 14. National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 1994-95 season.
    Can Commun Dis Rep; 1994 Jun; 20(11):85-92. PubMed ID: 7522728
    [No Abstract]   [Full Text] [Related]  

  • 15. National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 1992-93 season.
    Can Commun Dis Rep; 1992 May; 18(10):73-8. PubMed ID: 1284383
    [No Abstract]   [Full Text] [Related]  

  • 16. Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus.
    Martínez-Baz I; Navascués A; Pozo F; Chamorro J; Albeniz E; Casado I; Reina G; Cenoz MG; Ezpeleta C; Castilla J;
    Hum Vaccin Immunother; 2015; 11(7):1626-33. PubMed ID: 25996366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.
    Skowronski DM; De Serres G; Dickinson J; Petric M; Mak A; Fonseca K; Kwindt TL; Chan T; Bastien N; Charest H; Li Y
    J Infect Dis; 2009 Jan; 199(2):168-79. PubMed ID: 19086914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early estimates of influenza vaccine effectiveness in Navarre, Spain: 2012/13 mid-season analysis.
    Castilla J; Martinez-Baz I; Martinez-Artola V; Fernandez-Alonso M; Reina G; Guevara M; Garcia Cenoz M; Elia F; Alvarez N; Barricarte A; Ezpeleta C
    Euro Surveill; 2013 Feb; 18(7):2. PubMed ID: 23449182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza vaccine 2007-2008.
    Med Lett Drugs Ther; 2007 Oct; 49(1271):81-3. PubMed ID: 17912142
    [No Abstract]   [Full Text] [Related]  

  • 20. Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the I-MOVE multicentre case-control study, 2012/13.
    Valenciano M; Kissling E;
    Euro Surveill; 2013 Feb; 18(7):3. PubMed ID: 23449183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.